Nimbus Therapeutics - Articles and news items

NDI-010976

Nimbus initiates Phase I clinical programme for NDI-010976 for the treatment of NASH

Industry news / 22 April 2015 / Victoria White

Nimbus Therapeutics has initiated a Phase I clinical programme for NDI-010976 for the treatment of NASH and related fatty liver disease-spectrum disorders…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+